

VHL Antibody (monoclonal) (M01)

Mouse monoclonal antibody raised against a partial recombinant VHL. Catalog # AT4511a

Specification

VHL Antibody (monoclonal) (M01) - Product Information

Application IF, WB, E **Primary Accession** P40337 NM 000551 Other Accession Reactivity Human Host mouse Clonality **Monoclonal** Isotype IgG2b Kappa Calculated MW 24153

VHL Antibody (monoclonal) (M01) - Additional Information

Gene ID 7428

Other Names

Von Hippel-Lindau disease tumor suppressor, Protein G7, pVHL, VHL

Target/Specificity

VHL (NP 000542, 1 a.a. ~ 110 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.

Dilution

WB~~1:500~1000

Format

Clear, colorless solution in phosphate buffered saline, pH 7.2.

Storage

Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.

Precautions

VHL Antibody (monoclonal) (M01) is for research use only and not for use in diagnostic or therapeutic procedures.

VHL Antibody (monoclonal) (M01) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- Immunohistochemistry




- <u>Immunofluorescence</u>
- Immunoprecipitation
- Flow Cytomety
- Cell Culture


VHL Antibody (monoclonal) (M01) - Images



Immunofluorescence of monoclonal antibody to VHL on HeLa cell . [antibody concentration 10 ug/ml]



Antibody Reactive Against Recombinant Protein. Western Blot detection against Immunogen (38.21 KDa).




Western Blot analysis of VHL expression in transfected 293T cell line by VHL monoclonal antibody



(M01), clone 1G12.

Lane 1: VHL transfected lysate(19.7 KDa).

Lane 2: Non-transfected lysate.



Detection limit for recombinant GST tagged VHL is approximately 0.1ng/ml as a capture antibody.

VHL Antibody (monoclonal) (M01) - Background

Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed.

VHL Antibody (monoclonal) (M01) - References

Biomarkers Predicting Outcome in Patients with Advanced Renal Cell Carcinoma: Results from Sorafenib Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. Pe?a C, et al. Clin Cancer Res, 2010 Sep 14. PMID 20651059. Variation at the NFATC2 Locus Increases the Risk of Thiazolinedinedione-Induced Edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) Study. Bailey SD, et al. Diabetes Care, 2010 Jul 13. PMID 20628086. A Large-scale genetic association study of esophageal adenocarcinoma risk. Liu CY, et al. Carcinogenesis, 2010 Jul. PMID 20453000. Clinical and molecular features of familial and sporadic cases of von Hippel-Lindau disease from Mexico. Chacon-Camacho OF, et al. Clin Experiment Ophthalmol, 2010 Apr. PMID 20447124. VHL-gene deletion in single renal tubular epithelial cells and renal tubular cysts: further evidence for a cyst-dependent progression pathway of clear cell renal carcinoma in von Hippel-Lindau disease. Montani M, et al. Am J Surg Pathol, 2010 Jun. PMID 20431476.